Intellia Therapeutics Inc Stock
The Intellia Therapeutics Inc stock is trending slightly upwards today, with an increase of €0.015 (0.140%) compared to yesterday's price.
Currently there is a rather positive sentiment for Intellia Therapeutics Inc with 25 Buy predictions and 6 Sell predictions.
With a target price of 25 € there is potential for a 124.62% increase which would mean more than doubling the current price of 11.13 € for Intellia Therapeutics Inc.
Our community identified positive and negative aspects for Intellia Therapeutics Inc stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Intellia Therapeutics Inc stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
M***** P*******
Cons
?
S********** s********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Intellia Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | 0.140% | -2.027% | 13.395% | 26.020% | 42.390% | -67.037% | -79.688% |
| Chromadex Corp | 0.000% | -12.448% | -0.472% | -40.979% | -23.273% | 193.361% | -56.495% |
| Cardio3 Biosciences S.A. | -0.710% | -12.500% | 97.183% | -45.419% | 107.407% | -72.056% | -95.556% |
| Polynovo Ltd | -7.500% | 11.111% | 15.385% | -8.397% | -11.765% | -54.887% | -65.116% |
Comments
Intellia Therapeutics (NTLA) was upgraded by JonesTrading from "hold" to "buy". They now have a $29.00 price target on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NTLA) had its price target lowered by Canaccord Genuity Group Inc. from $54.00 to $48.00. They now have a "buy" rating on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by Brookline Capital Acquisition Corp..
Show more
Ratings data for NTLA provided by MarketBeat
News
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy?
Cathie Wood, the CEO of the investment management firm Ark Invest, is known for focusing on companies with significant innovative potential. One of her firm's picks, Intellia Therapeutics (NASDAQ:
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood seems to always be making market moves. The founder and CEO of Ark Invest publishes her transactions at the end of every trading day, and that gives us all a great way to track one of
This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?
Cathie Wood, the CEO of Ark Invest, is known for investing in companies with strong innovative potential. That includes biotechs that specialize in gene editing, a group of techniques that could
